Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals, obtaining the rights to develop its complement inhibitor drug compound APL-2 in ophthalmology. Financial terms were not disclosed.   Complement inhibition is a mechanism shown to reduce the growth of dry AMD. Potentia was the first company to develop a complement inhibitor for the treatment of AMD. APL-2 is in late preclinical development in ophthalmology and is expected to enter Phase II trials in patient...